Highlights from ISH 2007 | Oncolink - Cancer Resources

Oncolink Features

Find My Cancer Drug

Profesionales de la salud / / / /

A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group Presenter: Cacchione, RPresenter's Affiliation: CEMIC ArgentinaType of Session: ScientificBackground Non-Hodgkin’s Lymphoma (NHL) represents a diverse group of malignancies and has a variable presentation, ranging from indolent to...
A Phase 2 Study of 90Y-Zevammab in Relapsed Refractory Non-Hodgkin's Lymphoma: Preliminary Report of the Argentinean Cooperative Group The purpose of this prospective study was to address the efficacy of Yttrium ibritumomab tiuxetan (Zevalin) in patients with relapsed or refractory lymphomas who had already failed rituximab. Rituximab is a monocloncal antibody that targets CD20,...
Aberrant Methylation of Tumor Suppressor Genes (TSG) In Myeloma Multiple (MM) and Chronic Lymphocytic Leukemia (CLL) Presenter: Chena, C. and Stanganelli, C.Presenter's Affiliation: Academia Nacional de Medicina, ArgentinaType of Session: ScientificBackground Multiple myeloma (MM) is a clonal B-cell neoplasm that results from a number of mutations. Monoclonal...
Aberrant Methylation of Tumor Suppressor Genes (TSG) In Myeloma Multiple (MM) and Chronic Lymphocytic Leukemia (CLL) Presenter: Chena, C. and Stanganelli, C.Presenter's Affiliation: Academia Nacional de Medicina, ArgentinaType of Session: ScientificBackground Multiple myeloma (MM) is a clonal B-cell neoplasm that results from a number of mutations. Monoclonal...
Acute Lymphoblastic Leukemia (ALL): Detection of Prognostically Significance Fusion-Genes By Multiplex-Polymerase Chain Reaction (M-PCR) Presenter: Manrique, G.Presenter's Affiliation: ASESP, UruguayType of Session: ScientificBackground Acute lymphoblastic leukemia (ALL) is associated with a very poor prognosis in adults compared to the pediatric population. In children,...
Acute Myeloid Leukemia in the Elderly, Intensive or Maintenance Therapy? Our Experience in Patients Over 65 Years Presenter: Mettivier, VPresenter's Affiliation: Haematology Division A.Cardarelli Hospital, ItalyType of Session: ScientificBackground The use of intensive chemotherapy in the treatment of acute myeloid leukemia (AML) in patients older than age...
Acute Myeloid Leukemia in the Elderly, Intensive or Maintenance Therapy? Our Experience in Patients Over 65 Years When AML develops in people over the age of 65, the optimal choice of therapy is debatable. Intensive chemotherapy for AML is highly toxic, and there is great concern over causing more harm than good with this regimen. Many of these patients thus end...
Acute Promyelocytic Leukemia (APL): Genetic Characterization of 78 Argentinian And Uruguayan Patients Presenter: Uriarte, M.R.Presenter's Affiliation: ASESP, UruguayType of Session: ScientificBackground Acute Promyelocytic Leukemia (APL) requires accurate and rapid diagnosis of PML-RAR transcript for implementation of specific therapy,...
Acute Promyelocytic Leukemia, Twelve Years Experience at the University Hospital,San Juan, Puerto Rico Presenter: Lopez-Enriquez, A.Presenter's Affiliation: University of Puerto Rico, Puerto RicoType of Session: ScientificBackground Acute Promyelocytic Leukemias (APL) are a unique entity in the field of carcinogenesis. They result from maturation...
Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease Presenter: Gómez-Almaguer, DPresenter's Affiliation: Hospital Universitario de Nuevo León, MexicoType of Session: ScientificBackground Corticosteroid therapy is the mainstay of treatment for graft versus host disease (“GVHD). This condition is...
Alemtuzumab in the treatment of steroid refractory acute graft-versus-host disease Transplant patients take immunosuppressive medications for several years after undergoing transplantation. Graft Versus Host Disease (GVHD) is a common complication after allogeneic transplant that can have negative effects on the skin, liver, and...
Allogeneic Stem Cell Transplant with TBI/CY/Cytarabine Conditioning for Childhood Philadelphia-Positive ALL Presenter: Yoo, K.H.Presenter's Affiliation: Samsung Medical Center, KoreaType of Session: ScientificBackground Allogeneic stem cell transplantation (ASCT) is generally felt to be the optimal curative treatment of Philadelphia chromosome-positive...
Analysis of 511 Lymphoma Cases in Uruguay Presenter: Gualco, G. (in Spanish)Presenter's Affiliation: Hospital Militar, Laboratorio de Anatomía Patológica, UruguayType of Session: ScientificBackground The incidence and demographic distribution of Hodgkin's lymphoma (HL) and non-Hodgkin...
Correlation Between the Uptake of Tc-99m-sesta MIBI and Prognostic Factors in Patients with Multiple Myeloma Presenter: Bacovsky, J.M.Presenter's Affiliation: University of Olomouc, Czech RepublicType of Session: ScientificBackground Multiple myeloma (MM) is a malignant disease characterized by clonal proliferation and accumulation of transformed...
Cutaneous Lymphomas: Experience of a single institution in Lima-Perú Presenter: Beltran-Gárate, B.Presenter's Affiliation: Hospital Rebagliati, PeruType of Session: ScientificBackground It has been demonstrated that geographic variations can predict for the clinical behavior and pathologic characteristics of malignant...
Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib and Prognosis Presenter: Silveira, RAPresenter's Affiliation: UNICAMP, BrazilType of Session: ScientificBackground Imatanib (Gleevec) has been established as first line treatment in Chronic Myeloid Leukemia (CML). Resistance to Imatinib frequently...
Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 Patients from the Nordic Area Presenter: Björkstrand, BoPresenter's Affiliation: Huddinge University Hospital, SwedenType of Session: ScientificBackground Multiple myeloma (MM) is one of the most common indications for high-dose chemotherapy and transplantation in Sweden....
Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 Patients from the Nordic Area Multiple myeloma is commonly treated with stem cell transplantation in younger patients. A randomized study in 1996 found that double (or “tandem”) transplants resulted in an increase in overall survival, from 21% to 42% of patients. As a result,...
Expression of CD56 As A Prognostic Factor in Multiple Myeloma Presenter: Almeida, E. B.Presenter's Affiliation: Department of Internal Medicine and Hematology/Hemotherapy Center, State University of Campinas UNICAMP, BrazilType of Session: ScientificBackground Multiple myeloma (MM) is characterized by...
FLT3 gene internal tandem duplication (ITD) mutations in patients with acute myeloid leukemia (AML) Presenter: Arana-Trejo, RMPresenter's Affiliation: Genética, Hospital General de México and Laboratorio de OncoHematologia, SC, MexicoType of Session: ScientificBackground FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine...
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report Presenter: Milone, G.Presenter's Affiliation: Instituto de Investigaciones Hematologicas, Buenos Aires, ArgentinaType of Session: ScientificBackground Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated...
Fludarabine, mitoxantrone and dexamethasone as first line treatment of patients with indolent Non-Hodgkin's lymphoma (NHL): GATLA first interim report Advanced stage (Stage III/IV) indolent NHL is generally thought to be incurable, but can be treated successfully with chemotherapy as well as immunotherapy with or without linked radionuclides. Fludarabine (F) chemotherapy is at least as effective,...
In Vitro CD4+ T Cells Expansion: Induction of Regulatory T Cells with Sirolimus and CD3/CD28 Dynabeads Presenter: Borelli, GPresenter's Affiliation: Department of Cellular Therapy, Rikshospitalet-Radiumhospitalet HFType of Session: ScientificBackground T regulatory cells (Treg) are a subset of T lymphocytes defined by CD4+CD25+ markers and high...
Molecular Evaluation of Telomere length in patients with mantle cell lymphoma (MCL) Presenter: Cottliar, A.Presenter's Affiliation: Academia Nacional de Medicina, ArgentinaType of Session: ScientificBackground Mantle cell lymphoma (MCL) is a rare (6% of NHL), but aggressive NHL with median survival of 3-4 years. MCL is...
Monitoring Response to Imatinib By Fluorescence In Situ Hibridization (FISH) and Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) In Chronic Myeloid Leukemia (CML) Patients (PTS) In Chronic Phase (CP): Experience of Argentina and Uruguay Presenter: Pavlovsky, CPresenter's Affiliation: FUNDALEU (Argentina)Type of Session: ScientificBackground The impressive efficacy of imatinib in CML is well-established and is correlated directly with transcription levels of its target, bcr-abl....
Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia (ALL). Presenter: Gómez-Almaguer, DPresenter's Affiliation: Hospital Universitario de Nuevo León, MexicoType of Session: ScientificBackground Adult acute lymphoblastic leukemia (ALL) is associated with a far worse prognosis than in the pediatric...
Prognostic Factors for Malignant Transformation in Monoclonal Gammopathy of Undetermined Significance (MGUS): Experience of One Institution Presenter: Sackmann, FPresenter's Affiliation: FUNDALEU, ArgentinaType of Session: ScientificBackground MGUS has a prevalence of 1 to 3%. MGUS generally has an indolent course, however some patients (pts) will progress to a malignant...
Prognostic Value of CD38 Expression by Fluorescence Intensity Histogram in Chronic Lymphocytic Leukemia Presenter: Barreto, W.G. et al.Presenter's Affiliation: IAMSPE, São Paulo, Brasil and Universidade Federal de São Paulo, BrasilType of Session: ScientificBackground Chronic Lymphocytic Leukemia (CLL) is the most prevalent form of leukemia in...
Prognostic Value of CD38 Expression by Fluorescence Intensity Histogram in Chronic Lymphocytic Leukemia Presenter: Barreto, W. G.Presenter's Affiliation: Universidade Federal de São PauloType of Session: ScientificBackground Chronic Lymphocytic Leukemia (CLL) is the most prevalent form of leukemia in the Western World. CLL...
Prognostic Value of Different Profiles of the Early Response to Therapy in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Presenter: Semochkin, S.V.Presenter's Affiliation: Federal scientific clinical center for pediatric hematology, oncology and immunology, RussiaType of Session: ScientificBackground The early response of patients during induction therapy is essential...
Results in the Treatment With Chemotherapy in Acute Myeloid Leukemias. Experience of 20 Years Presenter: Hernández, C.Presenter's Affiliation: Hospital Hermanos Ameijeiras, CubaType of Session: ScientificBackground Acute myeloid leukemia (AML) represents 80% of the total number of acute leukemias that affect the adult Cuban population....
Results of the "Mexican method" to conduct allogeneic hematopoietic stem cell transplantation Presenter: Ruiz-Argüelles, GJPresenter's Affiliation: Centro de Hematologia y Medicina Interna de Puebla, MexicoType of Session: ScientificBackground Myeloablative allogeneic bone marrow transplantation is used for several hematopoietic...
Safety of Intrathecal Rituximab as Prophylaxis or Treatment in CD20+ Acute Lymphoblastic Leukemia (ALL) and Aggressive Lymphoma (AL): Report from a Mexican Pilot Study Presenter: Villela, L.Presenter's Affiliation: Instituto Nacional de Ciencias Médicas y Nutrición, MexicoType of Session: ScientificBackground CNS involvement in acute lymphoblastic leukemia (ALL) and aggressive lymphoma (AL) is a poor...
siRNA-Inhibition OF E2A-PBX1 in Pre-B Leukemia Cells Presenter: Casagrande, GPresenter's Affiliation: University of Padova - Lab. Pediatric Onco-Hematology, ItalyType of Session: ScientificBackground The t(1;19)(q23;p13) chromosomal translocation is detected in ~5-6% of childhood pre-B acute...
Therapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) for Relapsed or Untreated Progressive Chronic Lymphocytic Leukemia (CLL): A Single Centre Experience Presenter: Pavlovsky, M APresenter's Affiliation: FUNDALEU, ArgentinaType of Session: ScientificBackground Chronic lymphocytic leukemia (CLL) is an indolent neoplasm of B-cell origin, that is usually CD20+, CD5+, and CD23+. It is similar to small...

OncoLink I wish u knew...

Dr. Rebbeck talks about the role of cancer biology and genetics in cancer research and applying that to clinical care. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement